260 related articles for article (PubMed ID: 11996956)
1. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
3. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
4. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
5. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
7. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Ellen RL; McPherson R
Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
[TBL] [Abstract][Full Text] [Related]
10. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
12. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
[TBL] [Abstract][Full Text] [Related]
13. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
Farnier M; Ducobu J; Bryniarski L
Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Aberg JA; Zackin RA; Brobst SW; Evans SR; Alston BL; Henry WK; Glesby MJ; Torriani FJ; Yang Y; Owens SI; Fichtenbaum CJ;
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):757-67. PubMed ID: 16218799
[TBL] [Abstract][Full Text] [Related]
17. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares A
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
20. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate.
Feher MD; Caslake M; Foxton J; Cox A; Packard CJ
Diabetes Metab Res Rev; 1999; 15(6):395-9. PubMed ID: 10634964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]